BMS-986260

BMS-986260: sourced facts only. name: "Herein, we report the discovery, optimization, and evaluation of a potent, selective, and orally bioavailable TGFβR1 inhibitor, 10 (BMS-986260)." [1] target: "BMS-986260 is a small molecule, selective TGF-βR1 kinase inhibitor that was under preclinical development for oncology." [2] developer: "Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States." [1] stage: "Mechanism-based cardiovascular findings in the rat ultimately led to the termination of BMS-986260." [2] stage: "In summary, an intermittent-dosing schedule mitigated target-based cardiovascular toxicity in dogs but did not prevent valvulopathy in rats, and thus the development of BMS-986260 was terminated." [3] modality: "BMS-986260 is a small molecule, selective TGF-βR1 kinase inhibitor that was under preclinical development for oncology." [2]